Lesson
Name the Disease and Its Stage
Steatotic liver disease is an umbrella. MASLD requires hepatic steatosis plus cardiometabolic risk, while MASH adds hepatocellular injury and inflammation that can drive fibrosis.
- SLD
- MASLD
- MASH
- MetALD
- Fibrosis stage
nomenclature spectrum
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
Use current terms
MASLD and MASH replace historical NAFLD and NASH terminology. Older trials and labels may retain the historical terms, so translate them without changing the studied population.
Separate activity from stage
Steatosis and inflammatory activity can fluctuate, while fibrosis is the strongest liver-related prognostic feature. Normal aminotransferases do not exclude advanced disease.
Classify alcohol explicitly
Quantify amount, pattern, and time course. MetALD describes metabolic disease with alcohol exposure in a defined range, while greater exposure can shift the primary classification.
Name what changes care
Document F0 through F4 fibrosis context, current decompensation, cardiometabolic disease, and whether treatment eligibility has been established.
Quick check
Lesson
Follow Metabolic Stress to Fibrosis
Insulin resistance increases fatty-acid delivery and hepatic lipid production. Lipotoxicity, oxidative stress, cell injury, immune signaling, and stellate-cell activation connect metabolism to scar.
- Insulin resistance
- De novo lipogenesis
- Lipotoxicity
- Inflammation
- Stellate cells
pathobiology
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
Build the substrate load
Adipose insulin resistance increases free-fatty-acid flux, while hyperinsulinemia and carbohydrate excess promote hepatic de novo lipogenesis.
Distinguish storage from injury
Neutral triglyceride storage is not identical to toxic lipid signaling. Lipotoxic species, mitochondrial stress, and endoplasmic-reticulum stress can promote cell injury.
Connect injury to scar
Damaged hepatocytes and immune signaling activate stellate cells, which deposit extracellular matrix and remodel sinusoidal architecture.
Recognize heterogeneity
Genetics, visceral adiposity, diabetes, sleep apnea, diet, activity, medicines, alcohol, and social context alter progression even at similar body mass.
Quick check
Lesson
Confirm the Phenotype and Competing Causes
Steatosis can coexist with viral, alcohol-related, autoimmune, genetic, endocrine, nutritional, and medication-related injury.
- Metabolic criteria
- Alcohol exposure
- Viral hepatitis
- Medication review
- Genetic disease
risk secondary causes
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
Inventory metabolic risk
Assess adiposity, waist distribution, blood pressure, glucose status, lipids, sleep apnea, kidney disease, cardiovascular disease, and family history.
Quantify exposures
Review alcohol in standard drinks and grams, supplements, corticosteroids, amiodarone, tamoxifen, methotrexate, valproate, and other context-dependent contributors.
Exclude by probability
Use history, examination, hepatitis testing, iron studies, autoimmune evaluation, and age-specific genetic testing when clinical probability supports them.
Avoid a diagnosis of exclusion only
Positive metabolic criteria and steatosis establish MASLD, but coexistence matters because another disease can change urgency and treatment.
Quick check
Lesson
Start With a Simple Fibrosis Risk Gate
FIB-4 uses age, AST, ALT, and platelets to identify patients who can remain in primary care surveillance and those who need a second test.
- Age
- AST
- ALT
- Platelets
- FIB-4
fib4 screening
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
Calculate correctly
FIB-4 equals age multiplied by AST, divided by platelet count multiplied by the square root of ALT. Confirm units and current stable values.
Use common thresholds
In many adults, a value below 1.3 has useful negative predictive value. A value at least 1.3 generally prompts secondary assessment, while values above 2.67 increase concern.
Adapt for age
FIB-4 performs poorly below age 35. In adults older than 65, a higher lower threshold, commonly 2.0, reduces false positives.
Set reassessment cadence
Higher metabolic risk, especially type 2 diabetes or multiple risk factors, supports more frequent reassessment than a low-risk phenotype.
Quick check
Lesson
Resolve Risk With Elastography or ELF
Vibration-controlled transient elastography and ELF are common second-line tools. Magnetic resonance elastography and biopsy answer selected unresolved questions.
- VCTE
- ELF
- MRE
- Biopsy
- Referral
secondary assessment
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
Choose a second test
VCTE measures liver stiffness and can include steatosis assessment. ELF uses serum fibrosis markers. Interpret either within validated cutoffs and clinical context.
Check quality and confounders
Inflammation, congestion, cholestasis, recent food intake, body habitus, and technical reliability can distort stiffness.
Reserve advanced tools
MRE is highly accurate when uncertainty persists. Biopsy is useful for discordant tests, diagnostic uncertainty, or when histology will change a consequential decision.
Refer deliberately
High or discordant noninvasive risk, persistent enzyme elevation, suspected advanced fibrosis, or another liver disease warrants hepatology involvement.
Quick check
Lesson
Prescribe Lifestyle as Measurable Therapy
Nutrition, activity, sleep, alcohol reduction, and durable weight loss improve metabolic health and liver disease, but advice must become a supported plan.
- Weight loss
- Mediterranean pattern
- Exercise
- Alcohol
- Behavior support
lifestyle
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
Match weight loss to outcome
Even modest loss can reduce steatosis. Greater sustained loss, often above 10 percent, is more likely to improve MASH and fibrosis, although benefit is not limited to patients with obesity.
Build the eating pattern
Favor minimally processed foods, unsaturated fats, fiber, vegetables, legumes, whole grains, and reduced sugar-sweetened beverages within cultural and financial reality.
Prescribe activity
Aerobic and resistance activity can reduce liver fat and improve cardiometabolic fitness independent of major weight loss. Start from function and progress safely.
Design maintenance
Use dietitian access, behavioral treatment, anti-obesity therapy, bariatric evaluation when appropriate, sleep care, and scheduled follow-up to protect durability.
Quick check
Lesson
Treat the Major Competing Risk
Cardiovascular disease is a leading cause of death in MASLD. Lipids, blood pressure, diabetes, kidney disease, sleep apnea, tobacco, and obesity are liver care.
- ASCVD
- Statins
- Diabetes
- Obesity
- Sleep apnea
cardiometabolic care
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
Use statins appropriately
Statins are generally safe across the MASLD spectrum, including compensated cirrhosis when indicated. Monitor according to the drug and clinical context rather than avoiding treatment reflexively.
Choose diabetes therapy deliberately
Select glucose-lowering therapy for cardiovascular, kidney, weight, and liver context. Insulin may be necessary even though it can promote weight gain.
Treat obesity as disease
Combine behavior, pharmacotherapy, and metabolic surgery assessment when indicated. Weight loss can improve multiple causal drivers at once.
Protect the entire system
Address blood pressure, sleep apnea, tobacco, kidney disease, vaccination, reproductive goals, and access barriers in the same longitudinal plan.
Quick check
Lesson
Use Resmetirom as Targeted Thyroid-Hormone Biology
Resmetirom is a liver-directed thyroid hormone receptor beta agonist approved under accelerated approval for adults with noncirrhotic MASH and moderate-to-advanced fibrosis consistent with F2 to F3.
- THR-beta
- F2 to F3
- Weight-based dose
- CYP2C8
- OATP
resmetirom
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
Connect mechanism to effect
Selective hepatic THR-beta activation changes lipid metabolism, lowers hepatic fat and atherogenic lipids, and avoids intentional systemic THR-alpha stimulation.
Dose by actual body weight
The labeled dose is 80 mg once daily below 100 kg and 100 mg once daily at or above 100 kg, with or without food. Tablets are swallowed whole.
Screen interactions
Avoid strong CYP2C8 inhibitors such as gemfibrozil and OATP1B1 or OATP1B3 inhibitors such as cyclosporine. A moderate CYP2C8 inhibitor such as clopidogrel requires label-directed dose reduction.
Monitor the labeled risks
Watch for hepatotoxicity and gallbladder-related events. Resmetirom can increase exposure to selected statins, so follow labeled statin dose limits and assess liver or muscle toxicity.
Quick check
Lesson
Use Semaglutide for MASH and Metabolic Benefit
Wegovy is approved under accelerated approval for adults with noncirrhotic MASH and F2 to F3 fibrosis, alongside diet and increased physical activity.
- GLP-1 receptor
- F2 to F3
- Titration
- 2.4 mg weekly
- Boxed warning
semaglutide
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
Use the labeled population
The MASH indication is for adults with noncirrhotic disease and moderate-to-advanced fibrosis consistent with F2 to F3. Do not assume a weight-loss indication proves MASH eligibility.
Titrate to maintenance
Start 0.25 mg subcutaneously weekly for four weeks, then increase every four weeks through 0.5, 1, and 1.7 mg to 2.4 mg weekly. The label permits 1.7 mg if 2.4 mg is not tolerated.
Apply major safety screens
Avoid use with personal or family history of medullary thyroid carcinoma, MEN2, or serious hypersensitivity. Review pancreatitis, gallbladder disease, severe gastrointestinal symptoms, hypoglycemia risk with insulin or secretagogues, and dehydration-related kidney injury.
Counsel across transitions
Teach injection, missed-dose rules, symptom escalation, glucose monitoring when relevant, aspiration risk before procedures, and reproductive planning according to current labeling.
Quick check
Lesson
Choose Therapy by Phenotype and Follow Response
Resmetirom and semaglutide share an F2 to F3 noncirrhotic treatment boundary but differ in mechanism, route, metabolic effects, interactions, and adverse-effect profile.
- Eligibility
- Shared decision
- Baseline
- Response
- Persistence
selection monitoring
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
Confirm before prescribing
Verify adult noncirrhotic MASH with F2 to F3 fibrosis using appropriate noninvasive or histologic evidence and resolve discordant results.
Match phenotype
Semaglutide may align with obesity, diabetes, and cardiovascular goals. Resmetirom is oral and liver-directed but requires careful interaction and statin management.
Define baseline and follow-up
Record weight, waist, liver tests, glucose, lipids, fibrosis tests, symptoms, medicines, thyroid context when relevant, and treatment-specific safety variables.
Interpret response as a pattern
Follow adherence, tolerability, metabolic response, liver biochemistry, and validated fibrosis or imaging measures. Do not declare histologic cure from one enzyme value.
Quick check
Lesson
Recognize the Cirrhosis Boundary
F4 disease changes surveillance, portal-hypertension assessment, medication evidence, procedure risk, and transplant awareness. Disease-directed F2 to F3 labels should not be stretched across that boundary.
- F4
- HCC surveillance
- Portal hypertension
- Decompensation
- Investigational therapy
cirrhosis boundary
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
Do not miss advanced disease
Platelets, splenomegaly, nodular morphology, stiffness, collaterals, synthetic dysfunction, and prior decompensation can reveal cirrhosis even when symptoms are mild.
Activate surveillance
Cirrhosis generally requires HCC surveillance and portal-hypertension assessment, plus vaccination, nutrition, medication safety, and decompensation education.
Respect label boundaries
Resmetirom and semaglutide MASH approvals specify noncirrhotic F2 to F3 disease. Cirrhosis requires specialist decisions and evidence appropriate to that population.
Separate pipeline from practice
Agents such as efruxifermin remain investigational unless and until regulatory approval and current labeling establish a clinical role.
Quick check
Lesson
Build a Longitudinal MASLD Plan
A durable plan connects diagnostic certainty, fibrosis risk, metabolic disease, treatment eligibility, safety, behavior support, and ownership of future results.
- Stage
- Drivers
- Therapy
- Monitoring
- Ownership
integrated case
Connect metabolic load, liver injury, fibrosis risk, and treatment as one changing trajectory.
State the phenotype
Record current nomenclature, fibrosis evidence, alcohol exposure, competing causes, metabolic diseases, and cardiovascular risk.
Sequence the work
Move from FIB-4 to secondary testing when indicated, resolve discordance, and refer without waiting for decompensation.
Layer treatment
Use supported lifestyle care and cardiometabolic therapy for everyone, then add eligible disease-directed treatment with exact dosing and safety controls.
Close the loop
Assign dates and owners for laboratory monitoring, weight and metabolic follow-up, fibrosis reassessment, adverse-effect review, surveillance if cirrhosis emerges, and access barriers.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 120 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.